Positive topline data from Phase 1/2 clinical trial of INZ-701 in adults with ABCC6 Deficiency, showing improvements in vascular pathology, visual function, and patient reported outcomes.

Initial findings from natural history studies indicate a substantial disease burden among pediatric patients with ABCC6 Deficiency, with a high incidence of major clinical events.

Positive topline data from Phase 1/2 clinical trial of INZ-701 in adults with ENPP1 Deficiency, showing maintained favorable safety, immunogenicity, and clinical outcome data through 48 weeks.

Cash, cash equivalents, and short-term investments were $166.2 million as of March 31, 2024, expected to fund operations into the fourth quarter of 2025.